The landscape of multiple myeloma (MM) care in Dubai presents a dynamic challenge with diverse treatment patterns and comorbidity frequencies shaping patient outcomes. With the aim of scrutinizing the existing healthcare framework for MM in this unique region, this study delves into the disease burden, associated comorbidities, and consultation specialties, using a robust data set from the Dubai Real-World Claims Database (DRWD).
Analyzing the Patient Demographics
Between January 2014 and June 2023, 1,126 MM patients were evaluated with the median age bracket of 40-60 years emerging as the most affected. The cohort experiencing disease progression without remission, approximately 431 individuals, represented the largest group. The research reported incidence and prevalence rates varying from 2.6 to 4.2 and 2.9 to 4.7 per 100,000 population respectively, offering insights on the regional health burden.
Treatment Patterns and Consultation Preferences
Comorbid conditions significantly complicate the care of MM patients in Dubai; with diabetes and cardiovascular conditions topping the list at 88.3%. Nephropathy, neuropathy, and infections also represented a substantial share of the comorbidity landscape. While systemic treatments engaged 153 patients, and 35 opted for bone marrow transplants, substantial reliance on bortezomib, lenalidomide, and dexamethasone regimens was noted, particularly among non-transplant and transplant patients. Internal medicine, oncology, and hematology departments attracted the majority seeking professional medical advice.
The study offers several pivotal inferences:
- Increasing MM cases highlight an urgent demand for enhanced healthcare strategies.
- Dependency on specific drug regimens may indicate missing innovation in treatment diversity.
- High comorbidity incidence necessitates tailored care approaches for complex cases.
Gathering patient-centric data highlights the pressing need for structured health policies targeting MM in regions with diverse populations such as Dubai. With an expat-driven populace facing varied healthcare challenges, establishing comprehensive patient registries emerges as a non-negotiable step for sustainable healthcare solutions. The necessity for subsidized care pathways specific to MM ensures more equitable access, catering to complex patient needs efficiently. Observing healthcare practices through a data-driven lens presents real opportunities for clinical improvement and resource allocation, ultimately fostering better patient outcomes and a robust healthcare framework in the UAE. It is imperative for stakeholders to leverage these findings for informed policy and decision-making. By prioritizing integrated care models that address the unique health demographic nuances, Dubai can evolve as a leader in MM treatment and patient care excellence.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
